EMA 9/21 crossover, 4h, 95% of equity (vol-targeting study: baseline) · ETHUSDT 4h: +182.76%

EMA 9/21 crossover, 4h, 95% of equity (vol-targeting study: baseline) · ETHUSDT 4h: +182.76% — Janorium backtest